Skip to main content

Table 2 Response of HBeAg-positive patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to endpoint

From: Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Dose/Duration and endpoint EOT Time after end of treatment (years)
0.5 1 2 3 4 5
90 μg / 24 week
ALT normalization 1/4 0/4 0/4 0/4 0/4 0/4 0/4
HBeAg seroconversion 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Low HBV (<5 log copies/mL) 0/4 0/4 0/4 0/4 0/4 0/4 0/4
180 μg / 24 week
ALT normalization 0/4 0/4 0/4 1/4 0/3 0/3 0/3
HBeAg seroconversion 0/4 0/4 1/4 1/4 0/3 0/3 0/3
Low HBV (<5 log copies/mL) 2/4 0/4 1/4 2/4 0/3 0/3 0/3
90 μg/48 week
ALT normalization 0/4 2/4 1/3 2/3 1/3 2/3 2/3
HBeAg seroconversion 1/4 1/4 1/3 2/3 2/3 2/3 2/3
Low HBV (<5 log copies/mL) 1/4 2/4 1/3 2/3 2/3 2/3 2/3
180 μg/48 week
ALT normalization 1/5 3/5 2/5 2/5 2/4 1/4 1/4
HBeAg seroconversion 3/5 3/5 2/5 1/5 1/4 1/4 1/4
Low HBV (<5 log copies/mL) 4/5 1/5 1/5 1/5 1/4 1/4 1/4
  1. EOT end of treatment